Celldex Therapeutics, Inc. (CLDX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low5.6·High6.6
P/B Ratio
↓
4.09
+0% vs avg
5yr avg: 4.09
30Y Low0.3·High46.0
ROE
↓
-40.6%
↑-29% vs avg
5yr avg: -31.5%
30Y Low-413%·High-3%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CLDX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Celldex Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $1.8B | $1.6B | $1.9B | $2.1B | $1.7B | $519M | $32M | $31M | $365M | $359M |
| Enterprise Value | $2.1B | $1.8B | $1.6B | $1.9B | $2.1B | $1.6B | $479M | $25M | $12M | $331M | $317M |
| P/E Ratio → | -8.32 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1438.56 | 1204.09 | 231.80 | 279.16 | 886.63 | 356.16 | 70.00 | 9.05 | 3.28 | 28.65 | 52.96 |
| P/B Ratio | 4.09 | 3.43 | 2.18 | 4.48 | 6.41 | 3.95 | 2.48 | 0.34 | 0.25 | 1.54 | 1.35 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CLDX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1186.40 | 228.31 | 274.48 | 875.86 | 348.40 | 64.56 | 6.93 | 1.21 | 26.00 | 46.71 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CLDX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Celldex Therapeutics, Inc. earns an operating margin of -19160.0%. Operating margins have compressed from -2245.3% to -19160.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -40.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -2229.8% | -1614.5% | -3389.9% | -1046.2% | -473.4% | -1094.3% | -596.7% | -654.7% | -1403.5% |
| Operating Margin | -19160.0% | -19160.0% | -2778.9% | -2245.3% | -4889.0% | -1531.8% | -854.1% | -1540.2% | -1640.1% | -953.7% | -1958.7% |
| Net Profit Margin | -17253.3% | -17253.3% | -2248.8% | -2054.8% | -4765.6% | -1516.0% | -805.9% | -1424.0% | -1585.1% | -730.1% | -1894.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -40.6% | -40.6% | -26.8% | -37.4% | -30.1% | -22.4% | -39.4% | -46.7% | -83.9% | -37.1% | -46.3% |
| ROA | -37.6% | -37.6% | -25.1% | -34.6% | -28.2% | -20.7% | -33.3% | -36.5% | -64.1% | -26.6% | -35.7% |
| ROIC | -35.2% | -35.2% | -26.1% | -33.2% | -25.3% | -19.3% | -37.2% | -43.3% | -76.5% | -42.8% | -44.8% |
| ROCE | -44.7% | -44.7% | -32.9% | -40.2% | -30.2% | -21.9% | -38.1% | -43.2% | -72.6% | -38.2% | -40.6% |
CLDX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $29M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | 0.04 | 0.03 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.05 | -0.03 | -0.08 | -0.08 | -0.09 | -0.19 | -0.08 | -0.16 | -0.14 | -0.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($29M) exceeds total debt ($2M)
CLDX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Celldex Therapeutics, Inc.'s current ratio of 10.49x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 13.87x to 10.49x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.49 | 10.49 | 18.91 | 13.87 | 17.07 | 24.86 | 13.93 | 5.73 | 7.86 | 5.22 | 5.55 |
| Quick Ratio | 10.49 | 10.49 | 18.91 | 13.87 | 17.07 | 24.86 | 13.93 | 5.73 | 7.86 | 5.22 | 5.55 |
| Cash Ratio | 10.17 | 10.17 | 18.36 | 13.55 | 16.39 | 24.70 | 13.69 | 5.51 | 7.46 | 5.03 | 5.39 |
| Asset Turnover | — | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | 0.06 | 0.04 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 490.32 | 36.40 | 240.12 | 53.74 | 13.50 | 88.67 | 124.12 | 121.00 | 53.85 | 95.96 |
CLDX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Celldex Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $67M | $64M | $48M | $47M | $43M | $30M | $15M | $10M | $9M | $7M |
Peer Comparison
Compare CLDX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CLDXYou | $2B | -8.3 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 ARDX | $1B | -23.3 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 MGNX | $263M | -3.5 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 ALKS | $7B | 31.5 | 22.9 | 15.6 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 PTGX | $7B | -55.1 | — | 129.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CLDX — Frequently Asked Questions
Quick answers to the most common questions about buying CLDX stock.
What is Celldex Therapeutics, Inc.'s P/E ratio?
Celldex Therapeutics, Inc.'s current P/E ratio is -8.3x. This places it at the 50th percentile of its historical range.
What is Celldex Therapeutics, Inc.'s ROE?
Celldex Therapeutics, Inc.'s return on equity (ROE) is -40.6%. The historical average is -74.2%.
Is CLDX stock overvalued?
Based on historical data, Celldex Therapeutics, Inc. is trading at a P/E of -8.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Celldex Therapeutics, Inc.'s profit margins?
Celldex Therapeutics, Inc. has 100.0% gross margin and -19160.0% operating margin.